P00001606T0076 |0 10|ComparisonP00001606T
P00001606T0076 |42 56|5-nucleotidaseosphatases and
P00001606T0076 |16 37|alkaline phosphatasesomparison with alkali
P00008171T0000 |34 52|hyperbilirubinemiaaline phosphatases
P00008171T0000 |14 21|aspects Compar
P00008997A0472 |169 174|slope3-] i
P00008997A0472 |75 79|rats0081
P00008997A0472 |31 39|functionalkaline
P00008997A0472 |10 14|HCO30076
P00008997A0472 |56 60|data 5-n
P00008997A0472 |121 129|controlshyperbil
P00008997A0472 |43 51|CSF PCO2sphatase
P00008997A0472 |5 8|CSF160
P00010943A0733 |0 10|FlurazepamP00001606T
P00010943A0733 |122 127|nightyperb
P00010943A0733 |74 78|dose0008
P00010943A0733 |83 86|use000
P00010943A0733 |52 56|drug and
P00010943A0733 |98 106|practiceic aspec
P00010943A0733 |116 118|mgat
P00012653T0045 |0 4|BetaP000
P00012653T0045 |14 20|agents Compa
P00013683A0210 |20 31|CO2 removalrison with 
P00013683A0210 |61 65|VCO2cleo
P00013683A0210 |45 59|CO2 productionhatases and 5-
P00013683A0210 |77 88|ventilation8171T0000 P
P00015731A0090 |102 118|dichlorphenamidespects of neonat
P00015731A0090 |158 162|riseen C
P00015731A0090 |219 220|p 
P00015731A0090 |265 270|bloodcompa
P00015731A0090 |120 129|sulthiame hyperbil
P00015731A0090 |31 36|mg/kgalkal
P00015731A0090 |250 252|pHdi
P00015731A0090 |228 233|p CO2ed ra
P00015731A0090 |72 85|acetazolamideP00008171T000
P00015731A0090 |50 70|anhydrase inhibitorses and 5-nucleotidas
P00015731A0090 |87 100|methazolamidePharmacologic
P00015731A0090 |12 26|administration76 Comparison 
P00015731A0090 |207 215|increase the dat
P00015731A0090 |175 176|p 
P00015731A0090 |238 246|decreasee no lon
P00022143T0000 |50 56|rabbites and
P00022143T0000 |14 19|study Comp
P00022143T0000 |42 45|ratosp
P00022143T0000 |23 34|etoperidoneon with alk
P00023348A0601 |11 17|polyps076 Co
